US20160333108A1 - CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USE - Google Patents

CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USE Download PDF

Info

Publication number
US20160333108A1
US20160333108A1 US15/111,384 US201415111384A US2016333108A1 US 20160333108 A1 US20160333108 A1 US 20160333108A1 US 201415111384 A US201415111384 A US 201415111384A US 2016333108 A1 US2016333108 A1 US 2016333108A1
Authority
US
United States
Prior art keywords
cells
antigen
car
region
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/111,384
Other languages
English (en)
Inventor
Stephen J. Forman
Christine E. Brown
Umamaheswararao Jonnalagadda
Armen Mardiros
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
City of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City of Hope filed Critical City of Hope
Priority to US15/111,384 priority Critical patent/US20160333108A1/en
Assigned to CITY OF HOPE reassignment CITY OF HOPE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MARDIROS, Armen
Assigned to CITY OF HOPE reassignment CITY OF HOPE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MARDIROS, Armen
Publication of US20160333108A1 publication Critical patent/US20160333108A1/en
Assigned to CITY OF HOPE reassignment CITY OF HOPE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BROWN, Christine E., FORMAN, STEPHEN J., JONNALAGADDA, UMA MAHESWARA RAO
Assigned to CITY OF HOPE reassignment CITY OF HOPE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BROWN, Christine E., FORMAN, STEPHEN J., JONNALAGADDA, UMA MAHESWARA RAO
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/17—Hinge-spacer domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Definitions

  • CAR chimeric antigen receptor
  • CARs that contain a TAA-specific scFv that produces an intracellular signal via a cytoplasmic costimulatory (e.g., CD28 or 4-1BB) domain fused to CD3-zeta have been shown in various systems to exhibit significant anti-tumor potency (Brentjens et al. 2013; Brentjens et al. 2011; Grupp et al. 2013; Kalos et al. 2011; Kochenderfer et al. 2012), immunological rejection and clearance by the host remains a challenge to effective cancer treatment.
  • hinge/spacer sequences that do not originate from Ig Fc domains may be used, such as those from CD8 ⁇ or CD28 (Brentjens et al. 2007; Kalos et al. 2011; Imai et al. 2004; Kochenderfer et al. 2009).
  • these spacer sequences may alleviate FcR binding, their length may not endow CAR T cells with optimal potency when targeting certain antigens. For instance, when targeting 5T4, NCAM and MUC1 using CAR T cells, longer linker regions (i.e., longer than those derived from CD8 ⁇ or CD28) were required for optimal potency (Wilkie et al. 2008; Guest et al. 2005).
  • CAR chimeric antigen receptors having impaired binding to an Fc receptor
  • FcR Fc receptor
  • Such CARs may include, but are not limited to, an antigen recognition domain, a spacer domain derived from a modified immunoglobulin Fc region having one or more mutations in its CH2 region resulting in impaired binding to an FcR, and an intracellular signaling domain.
  • a population of human immune cells transduced by a viral vector comprising an expression cassette that includes a CAR gene comprises a nucleotide sequence that encodes an antigen recognition domain, a spacer domain derived from a modified immunoglobulin Fc region having one or more mutations in its CH2 region resulting in impaired binding to an FcR, and an intracellular signaling domain, wherein the population of human immune cells expresses the CAR gene.
  • a method of treating a cancer in a subject includes administering a population of human immune cells transduced with a CAR gene to the subject.
  • the CAR gene comprises a nucleotide sequence that encodes an antigen recognition domain that targets a cancer associated antigen specific to the cancer, a spacer domain derived from a modified immunoglobulin Fc region having one or more mutations in its CH2 region resulting in impaired binding to an FcR, and an intracellular signaling domain.
  • Designing a CAR having a spacer domain that has decreased or impaired binding to FcRs helps prevent the FcR-expressing cells from recognizing and destroying, or unintentionally activating, the CAR-expressing immunotherapeutic cells in vivo. Therefore, such CARs help prevent immunological rejection and clearance of the cells meant to provide therapeutic benefit to patients
  • FIG. 1 shows that CD19-specific CAR-expressing T cells do not efficiently engraft in NSG mice according to one embodiment.
  • FIG. 1 a shows the schematics of the CD19R/EGFRt (top) and EGFRt (bottom) expression constructs that were used to gene modify T cells for engraftment studies.
  • FIG. 1 b is a flow cytometric analysis of T cells administered to NSG mice for engraftment studies.
  • T CM -derived cells were left non-transduced (Non-Txd), or were transduced with lentiviral vectors containing the CD19R/EGFRt (CD19R) or EGFRt/DHFRFS/IMPDH2IY (EGFRt) constructs described in (A) and immunomagnetically selected for EGFRt-expression.
  • the cells were then expanded in vitro for 19 days and analyzed for surface phenotype. Percentages of cells staining with antibodies specific for CD4 (top) or CD8 (bottom) vs. EGFRt are indicated in each histogram, using quadrants that were created based on negative control staining.
  • FIG. 2 illustrates that CD19-specific CAR-expressing T cells bind soluble Fc ⁇ R1 according to one embodiment.
  • the same T cells described in FIG. 1 were stained with the indicated volume titration of biotinylated soluble human Fc gamma receptor 1 followed by PE-conjugated streptavidin (SA-PE, grey histogram).
  • SA-PE PE-conjugated streptavidin
  • percentages of immune reactive cells are indicated in each histogram, and based on an M1 gate set to detect ⁇ 1% of that stained with SA-PE alone (black line).
  • FIG. 3 shows that a mutated IgG4 spacer does not affect CD19-specific effector function of CAR-expressing T cells according to one embodiment.
  • FIG. 3 a shows the schematics of the parental CD19-specific CAR (CD19R), the CD19-specific CAR that contains the 2 point mutations, L235E and N297Q, in the CH2 portion of the IgG4 spacer (CD19R(EQ)), and the CD19-specific CAR that contains a truncated IgG4 spacer, where the whole CH2 domain is removed (CD19Rch2 ⁇ ).
  • Percentages of cells staining with antibodies specific for the Fc-containing CAR (top) or EGFRt (bottom) are indicated in each histogram, and based on an M1 gate set to detect ⁇ 1% of that stained with SA-PE alone (black line).
  • FIG. 3 c the same cells used in FIG. 3 b were used as effectors in a 4-hour chromium release assay against 51 Cr-labeled CD19 + LCL or SupB15 targets.
  • LCL expressing the CD3 agonist OKT3 (LCL-OKT3) and CD19-negative K562 cells were used as positive- and negative-control targets, respectively.
  • Mean percent chromium release ⁇ S.D. of triplicate wells at the indicated E:T ratios are depicted.
  • FIG. 4 shows that CARs with a mutated IgG4 spacer exhibit inhibited Fc ⁇ R binding according to one embodiment.
  • TCM-derived, EGFRt-enriched, expanded cell lines expressing either the EGFRt marker alone, the parental CD19R, the single point-mutated CD19R(L235E) or CD19R(N297Q), the double point-mutated CD19R(EQ), or the CH2-deleted CD19Rch2 ⁇ were stained with the following biotinylated reagents: anti-Fc antibody (to detect the CAR), cetuximab (to detect EGFRt), or the indicated human (Hu) or murine (Mu) soluble Fc receptors (Fc ⁇ R1, R2a, or R2b); followed by PE-conjugated streptavidin (SA-PE, grey histogram). Percentages of immune reactive cells are indicated in each histogram, and based on an M1 gate set to detect ⁇ 1% of that stained with SA-PE alone (black
  • FIG. 5 shows that T cells expressing CARs with mutated IgG4 spacer exhibit enhanced in vivo engraftment according to one embodiment.
  • 10 7 T CM -derived, EGFRt-enriched cells expressing either the parental CD19R, the EGFRt marker alone, the single point-mutated CD19R(L235E) or CD19R(N297Q), the double point-mutated CD19R(EQ), or the CH2-deleted CD19Rch2 ⁇ (see phenotype FIG. 3 b ) were infused i.v. into NSG mice on day 0 with irradiated NS0-IL15 support.
  • FIG. 5 a mean percentages of CD45+ EGFRt+ cells in the viable lymphocyte-gated population ⁇ S.E.M. are indicated. *, p ⁇ 0.034 when compared to mice given CD19R-expressing cells using an unpaired Student's t-test.
  • FIG. 5 b shows representative histograms (i.e., median 3 of each group of 5 mice) that are depicted with quadrants created based on control staining. Percentages of huCD45+ EGFRt+ cells are indicated in each histogram.
  • FIG. 6 shows that T CM -derived cells expressing CARs with mutated IgG4 spacer exhibit enhanced therapeutic efficacy according to some embodiments.
  • 1.5 ⁇ 10 6 ffLuc + LCL cells were administered i.v. into NSG mice on day 0, and then 5 ⁇ 10 6 CAR+ T CM -derived cells (10 7 cells total) expressing either the EGFRt marker alone, the parental CD19R, the double point-mutated CD19R(EQ), or the CH2-deleted CD19Rch2 ⁇ were infused i.v. into NSG mice on day 3.
  • LCL tumor growth was then monitored by Xenogen imaging.
  • FIG. 6 a shows a flow cytometric analysis depicting the CAR profiles of the input T CM -derived cells (used at day 23 after bead stimulation and lentitransduction). Percentages of immunoreactive cells are indicated in each histogram, and based on an M1 gate set to detect ⁇ 1% of that stained with SA-PE alone (black line).
  • FIG. 6 c shows representative bioluminescence images of NSG mice at day 21 are depicted for each group.
  • FIG. 6 d shows mean percentages (+S.E.M.) of CD45 + EGFRt + cells in the viable lymphocyte-gated population of peripheral blood at day 21 are indicated. *, p ⁇ 0.035 when compared to mice given CD19R-expressing cells using an unpaired Student's t-test.
  • FIG. 7 shows that bulk T cells expressing CD19R(EQ) exhibit enhanced therapeutic efficacy according to one embodiment.
  • 1.5 ⁇ 10 6 ffLuc + LCL cells were administered i.v. into NSG mice on day 0, and then 5 ⁇ 10 6 CAR + T cells expressing either the parental CD19R or the double point-mutated CD19R(EQ) were infused i.v. into NSG mice on day 2.
  • LCL tumor growth was then monitored by Xenogen imaging.
  • FIG. 7 a shows a flow cytometric analysis of the CAR (top), EGFRt vs. CD3 (middle) and CD4 vs CD8 (bottom) profiles of the input T cells (used at day 21 after bead stimulation and lentitransduction).
  • FIG. 7 b shows representative bioluminescence images of NSG mice at day 2, 11 and 23 are depicted for each group.
  • FIG. 8 shows that non-enriched T CM -derived cells expressing CARs with mutated IgG4 spacer exhibit enhanced in vivo engraftment according to some embodiments.
  • 10 7 T CM -derived cells expressing either the EGFRt marker alone, the parental CD19R, or the double point-mutated CD19R(EQ) were infused i.v. into NSG mice on day 0 with irradiated NS0-IL15 support.
  • FIG. 10 7 T CM -derived cells expressing either the EGFRt marker alone, the parental CD19R, or the double point-mutated CD19R(EQ) were infused i.v. into NSG mice on day 0 with irradiated NS0-IL15 support.
  • FIG. 8A shows a flow cytometric analysis depicting the CAR profiles of the input T CM -derived cells (used at day 26 after bead stimulation and lentitransduction). Percentages of cells staining with antibodies specific for the Fc-containing CAR (top) or EGFRt (bottom) are indicated in each histogram, and based on an M1 gate set to detect 1% of that stained with SA-PE alone (black line).
  • FIG. 8B shows mean percentages of CD45+EGFRt+ cells in the viable lymphocyte-gated population ⁇ S.E.M. are indicated.
  • FIG. 8C shows representative histograms (i.e., median 2 of each group of 4-6 mice) are depicted with quadrants created based on control staining. Percentages of huCD45+ EGFRt+ cells are indicated in each histogram.
  • a CAR may include a series of protein or peptide domains including, but not limited to, one or more of an antigen binding domain, a spacer domain, a transmembrane domain, an intracellular signaling domain and an intracellular costimulatory domain.
  • a gene encoding the CAR is provided, wherein the gene includes a nucleotide or nucleic acid sequence which includes a series of regions which encode an amino acid sequence corresponding to the protein or peptide domains of the CAR described herein. Because the degeneracy of the genetic code is known, any amino acid sequences disclosed herein are also indicative of all degenerate nucleic acid codons corresponding to each amino acid in said sequences. As such, it is understood that the embodiments describing CARs and their domains may be provided as a gene comprising a nucleic acid sequence as well as the amino acid sequences encoded by said genes.
  • a CAR may include, but is not limited to, an antigen binding domain, a spacer domain, optionally at least one intracellular signaling domain and optionally at least one intracellular costimulatory domain.
  • a CAR may include, but is not limited to, an antigen binding domain, a spacer domain, and at least one intracellular signaling domain.
  • a CAR may include, but is not limited to, an antigen binding domain, a spacer domain, at least one intracellular signaling domain and at least one intracellular costimulatory domain.
  • a CAR antigen binding domain may include a nucleotide sequence that, when expressed as a peptide or polypeptide, binds an epitope of a cancer-related antigen.
  • a cancer-related antigen may be any antigen expressed by or overexpressed by a cancer cell (e.g., a tumor cell, a neoplastic cell, a malignant cell, or any other cancerous cell), and may be a protein, peptide, carbohydrate, glycoprotein, ganglioside, proteoglycan, or any combination or complex thereof.
  • the cancer-related antigen is a tumor specific antigen (TSA) that may be expressed only on cancer or tumor cells, while in other aspects, the cancer-related antigen is a tumor-associated antigen (TAA) that may be expressed on both tumor cells and normal cells.
  • TSA tumor specific antigen
  • TAA tumor-associated antigen
  • the cancer-related antigen may be a product of a mutated oncogene or tumor suppressor gene, or a product of another mutated gene (e.g., overexpressed or aberrantly expressed cellular proteins, tumor antigens produced by oncogenic viruses, oncofetal antigens, altered cell surface glycolipids or glycoproteins, or cell type-specific differentiation antigens).
  • cancer-related antigens that may be targeted by a CAR antigen binding domain described herein include, but are not limited to, 5T4, 8H9, ⁇ v ⁇ 6 integrin, alphafetoprotein (AFP), B7-H6, CA-125 carbonic anhydrase 9 (CA9), CD19, CD20, CD22, CD30, CD33, CD38, CD44, CD44v6, CD44v7/8, CD52, CD123, CD171, carcionoembryonic antigen (CEA), EGFrvIII, epithelial glycoprotein-2 (EGP-2), epithelial glycoprotein-40 (EGP-40), ErbB1/EGFR, ErbB2/HER2/neu/EGFR2, ErbB3, ErbB4, epithelial tumor antigen (ETA), FBP, fetal acetylcholine receptor (AchR), folate receptor- ⁇ , G250/CAIX, ganglioside 2 (GD2), ganglioside 3 (GD
  • mucin-16 MUC16
  • natural killer group 2 member D NCAM
  • NY-ESO-1 Oncofetal antigen (h5T4)
  • PSCA prostate stem cell antigen
  • PSMA prostate-specific membrane antigen
  • ROR1 receptor-tyrosine kinase-like orphan receptor 1
  • TAA targeted by mAb IgE TAA targeted by mAb IgE
  • TAA targeted by mAb IgE tumor-associated glycoprotein-72 (TAG-72), tyrosinase, and vascular endothelial growth factor (VEGF) receptors.
  • TAA targeted by mAb IgE TAA targeted by mAb IgE
  • TAA tumor-associated glycoprotein-72
  • TAG-72 tumor-associated glycoprotein-72
  • VEGF vascular endothelial growth factor
  • the antigen binding domain that is part of a CAR described herein targets CD19 or CD123.
  • an antigen binding domain may be any targeting moiety which targets an antigen associated with cancer.
  • the antigen binding domain is an antibody or functional fragment of an antibody.
  • An antibody refers to an immunoglobulin molecule that specifically binds to, or is immunologically reactive with an antigen or epitope, and includes both polyclonal and monoclonal antibodies, as well as functional antibody fragments, including but not limited to fragment antigen binding (Fab) fragments, F(ab′)2 fragments, Fab′ fragments, Fv fragments, recombinant IgG (rIgG) fragments, single chain variable fragments (scFv) and single domain antibodies (e.g., sdAb, sdFv, nanobody) fragments.
  • Fab fragment antigen binding
  • F(ab′)2 fragments fragment antigen binding
  • Fab′ fragments fragment antigen binding
  • Fv fragments fragment antigen binding
  • rIgG recombinant IgG
  • scFv single chain
  • antibody or functional fragment thereof also includes genetically engineered or otherwise modified forms of immunoglobulins, such as intrabodies, peptibodies, chimeric antibodies, fully human antibodies, humanized antibodies, and heteroconjugate antibodies (e.g., bispecific antibodies, diabodies, triabodies, tetrabodies, tandem di-scFv, tandem tri-scFv). Unless otherwise stated, the term “antibody” should be understood to encompass functional antibody fragments thereof.
  • the antigen binding domain is an scFv having a heavy (V H ) and light chain (V L ).
  • the antigen binding domain is an scFv that targets CD19 or CD123.
  • the scFv that targets CD19 may have the following amino acid sequence:
  • CD19R V L (SEQ ID NO: 1) DIQMTQTTSS LSASLGDRVT ISCRASQDIS KYLNWYQQKP DGTVKLLIYH TSRLHSGVPS RFSGSGTD YSLTISNLEQ EDIATYFCQQ GNTLPYTFGG GTKLEIT CD19R V H (SEQ ID NO: 2) EVKLQESGPG LVAPSQSLSV TCTVSGVSLP DYGVSWIRQP PRKGLEWLGV IWGSETTYYN SALKSRLTII KDNSKSQVFL KMNSLQTDDT AIYYCAKHYY YGGSYAMDYW GQGTSVTVSS
  • scFv that targets CD123 may have one of the following amino acid sequences:
  • the spacer domain may be derived from or include at least a portion of an immunoglobulin Fc region, for example, an IgG1 Fc region, an IgG2 Fc region, an IgG3 Fc region, an IgG4 Fc region, an IgE Fc region, an IgM Fc region, or an IgA Fc region.
  • the spacer domain includes at least a portion of an IgG1, an IgG2, an IgG3, an IgG4, an IgE, an IgM, or an IgA immunoglobulin Fc region that falls within its CH2 and CH3 domains.
  • the spacer domain may also include at least a portion of a corresponding immunoglobulin hinge region.
  • the spacer domain is derived from or includes at least a portion of a modified immunoglobulin Fc region, for example, a modified IgG1 Fc region, a modified IgG2 Fc region, a modified IgG3 Fc region, a modified IgG4 Fc region, a modified IgE Fc region, a modified IgM Fc region, or a modified IgA Fc region.
  • the modified immunoglobulin Fc region may have one or more mutations (e.g., point mutations, insertions, deletions, duplications) resulting in one or more amino acid substitutions, modifications, or deletions that cause impaired binding of the spacer domain to an Fc receptor (FcR).
  • mutations e.g., point mutations, insertions, deletions, duplications
  • FcR Fc receptor
  • the modified immunoglobulin Fc region may be designed with one or more mutations which result in one or more amino acid substitutions, modifications, or deletions that cause impaired binding of the spacer domain to one or more FcR including, but not limited to, Fc ⁇ RI, Fc ⁇ R2A, Fc ⁇ R2B1, Fc ⁇ R2B2, Fc ⁇ R3A, Fc ⁇ R3B, Fc ⁇ RI, Fc ⁇ R2, Fc ⁇ RI, Fc ⁇ / ⁇ R, or FcRn.
  • FcRs such as Fc ⁇ RI
  • NK natural killer cells
  • macrophages which then use this Fc-targeting ability to carry out various immune functions such as antibody-dependent cell-mediated cytotoxicity (ADCC) and phagocytosis.
  • ADCC antibody-dependent cell-mediated cytotoxicity
  • Impairment of binding to FcRs by the spacer domain prevents the FcR-expressing cells from recognizing and destroying, or unintentionally activating, the CAR-expressing immunotherapeutic cells in vivo, thereby helping to prevent immunological rejection and clearance of the cells meant to provide therapeutic benefit to patients.
  • the mutations described herein also contribute to reducing the CAR's off-target effects and, thereby increasing its specificity and efficacy.
  • amino acid modification or an “amino acid substitution” or a “substitution,” as used herein, mean an amino acid substitution, insertion, and/or deletion in a protein or peptide sequence.
  • amino acid substitution or “substitution” as used herein, means a replacement of an amino acid at a particular position in a parent peptide or protein sequence with another amino acid.
  • substitution S228P refers to a variant protein or peptide, in which the serine at position 228 is replaced with proline.
  • Amino acid substitutions can be made by a mutation such that a particular codon in the nucleic acid sequence encoding the protein or peptide is changed to a codon which codes for a different amino acid. Such a mutation is generally made by making the fewest nucleotide changes possible.
  • a substitution mutation of this sort can be made to change an amino acid in the resulting protein in a non-conservative manner (i.e., by changing the codon from an amino acid belonging to a grouping of amino acids having a particular size or characteristic to an amino acid belonging to another grouping) or in a conservative manner (i.e., by changing the codon from an amino acid belonging to a grouping of amino acids having a particular size or characteristic to an amino acid belonging to the same grouping).
  • Such a conservative change generally leads to less change in the structure and function of the resulting protein.
  • Amino acids with nonpolar R groups Alanine, Valine, Leucine, Isoleucine, Proline, Phenylalanine, Tryptophan, Methionine.
  • Amino acids with uncharged polar R groups Glycine, Serine, Threonine, Cysteine, Tyrosine, Asparagine, Glutamine.
  • Amino acids with charged polar R groups (negatively charged at Ph 6.0): Aspartic acid, Glutamic acid.
  • Basic amino acids (positively charged at pH 6.0): Lysine, Arginine, Histidine (at pH 6.0).
  • Another grouping may be those amino acids with phenyl groups: Phenylalanine, Tryptophan, Tyrosine.
  • Another grouping may be according to molecular weight (i.e., size of R groups) as shown below:
  • the spacer domain is derived from a modified IgG1, IgG2, IgG3, or IgG4 Fc region that includes one or more amino acid residues substituted with an amino acid residue different from that present in an unmodified hinge.
  • the one or more substituted amino acid residues are selected from, but not limited to one or more amino acid residues at positions 220, 226, 228, 229, 230, 233, 234, 235, 234, 237, 238, 239, 243, 247, 267, 268, 280, 290, 292, 297, 298, 299, 300, 305, 309, 218, 326, 330, 331, 332, 333, 334, 336, 339, or a combination thereof.
  • the spacer domain is derived from a modified IgG1, IgG2, IgG3, or IgG4 Fc region that includes, but is not limited to, one or more of the following amino acid residue substitutions: C220S, C226S, S228P, C229S, P230S, E233P, V234A, L234V, L234F, L234A, L235A, L235E, G236A, G237A, P238S, S239D, F243L, P2471, S267E, H268Q, S280H, K290S, K290E, K290N, R292P, N297A, N297Q, S298A, S298G, S298D, S298V, T299A, Y300L, V305I , V309L, E318A, K326A, K326W, K326E, L328F, A330L, A330S, A
  • the spacer domain is derived from an IgG Fc region having one or more modifications made to its CH2-CH3 region, wherein the unmodified IgG CH2-CH3 region corresponds to one of the following amino acid sequences:
  • the spacer domain is derived from an IgG Fc region having one or more modifications made to its hinge region, wherein the unmodified IgG hinge region corresponds to one of the following amino acid sequences:
  • EPKSCDKTHTCPPCP IgG2 (SEQ ID NO: 12)
  • ERKCCVECPPCP IgG3 (SEQ ID NO: 13)
  • ELKTPLGDTTHTCPRCPEPKSCDTPPPCPRCP EPKSCDTPPPCPRC PEPKSCDTPPPCPRCP IgG4 (SEQ ID NO: 14)
  • the spacer domain is derived from an IgG4 Fc region having the following amino acid sequence:
  • the spacer domain is derived from a modified IgG4 Fc that includes one or more amino acid residues substituted with an amino acid residue different from that present in an unmodified IgG4 Fc region.
  • the one or more substituted amino acid residues are selected from, but not limited to one or more amino acid residues at positions 220, 226, 228, 229, 230, 233, 234, 235, 234, 237, 238, 239, 243, 247, 267, 268, 280, 290, 292, 297, 298, 299, 300, 305, 309, 218, 326, 330, 331, 332, 333, 334, 336, 339, 396, or a combination thereof.
  • the spacer domain is derived from a modified IgG4 Fc region that includes, but is not limited to, one or more of the following amino acid residue substitutions: 220S, 226S, 228P, 229S, 230S, 233P, 234A, 234V, 234F, 234A, 235A, 235E, 236A, 237A, 238S, 239D, 243L, 2471, 267E, 268Q, 280H, 290S, 290E, 290N, 292P, 297A, 297Q, 298A, 298G, 298D, 298V, 299A, 300L, 305I, 309L, 318A, 326A, 326W, 326E, 328F, 330L, 330S, 331S, 331S, 332E, 333A, 333S, 333S, 334A, 339D, 339Q, 396L, or a combination thereof
  • the spacer domain is derived from a modified IgG4 Fc region that includes, but is not limited to, two or more (i.e., “double mutated”), three or more (i.e., “triple mutated”), four or more, five or more, or more than five of the following amino acid residue substitutions: 220S, 226S, 228P, 229S, 230S, 233P, 234A, 234V, 234F, 234A, 235A, 235E, 236A, 237A, 238S, 239D, 243L, 2471, 267E, 268Q, 280H, 290S, 290E, 290N, 292P, 297A, 297Q, 298A, 298G, 298D, 298V, 299A, 300L, 305I, 309L, 318A, 326A, 326W, 326E, 328F, 330L, 330S, 331S
  • the spacer domain is derived from a modified IgG4 Fc region that includes, but is not limited to, a substitution of proline (P) in place of serine (S) at position 228 (S228P), a substitution of leucine (L) in place of glutamic acid (E) at position 235 (L235E), a substitution of asparagine (N) in place of glutamine (Q) at position 297 (N297Q), or a combination thereof.
  • a modified IgG4 Fc region has a single mutation, as indicated in the following amino acid sequences (mutations are in bold and underlined):
  • the spacer domain is derived from a modified IgG4 Fc region that is double mutated to include an L235E substitution and an N297Q substitution (“EQ”).
  • the modified IgG4 Fc region is triple mutated to include an S228P substitution, an L235E substitution, and an N297Q substitution (“S228P+L235E+N297Q”).
  • a modified IgG4 Fc and/or hinge region may include a nucleotide sequence which encodes an amino acid sequence selected from the following (mutations are in bold and underlined):
  • ESKYGPPCPS CPAPEF E GGP SVFLFPPKPK DTLMISRTPE VTCVVVDVSQ EDPEVQFNWY VDGVEVHNAK TKPREEQF Q S TYRVVSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK AKGQPREPQV YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS RLTVDKSRWQ EGNVFSCSVM HEALHNHYTQ KSLSLSLGK (S228P + L235E + N297Q mutation; SEQ ID NO: 19) ESKYGPPCP P CPAPEF E GGP SVFLFPPKPK DTLMISRTPE VTCVVVDVSQ EDPEVQFNWY VDGVEVHNAK TKPREEQF Q S TYRVVSVLTV LHQDWLNGKE YKCKVS
  • the spacer domain is derived from a modified immunoglobulin Fc region that includes one or more deletions of all of a part of its CH2 domain. In one embodiment, the spacer domain is derived from a modified IgG4 Fc region that includes one or more deletions of all of a part of its CH2 domain (“ch2 ⁇ ”). In one aspect of such an embodiment, the spacer domain may include a nucleotide sequence which encodes the following amino acid sequence:
  • the spacer domain may be modified to substitute the immunoglobulin Fc region for a spacer that does not have the ability to bind FcR, such as the hinge region of CD8a.
  • the Fc spacer region of the hinge may be deleted. Such substitutions would reduce or eliminate Fc binding.
  • position is a location in the sequence of a protein. Positions may be numbered sequentially, or according to an established format, for example a Kabat position or an EU position or EU index as in Kabat. For all positions discussed herein, numbering is according to the EU index or EU numbering scheme (Kabat et al., 1991, Sequences of Proteins of Immunological Interest, 5th Ed., United States Public Health Service, National Institutes of Health, Bethesda, hereby entirely incorporated by reference).
  • the EU index or EU index as in Kabat or EU numbering scheme refers to the numbering of the EU antibody (Edelman et al., 1969, Proc Natl Acad Sci USA 63:78-85, which is hereby entirely incorporated by reference).
  • Kabat positions while also well known in the art, may vary from the EU position for a given position.
  • the S228P and L235E substitutions described above refer to the EU position.
  • these substitutions may also correspond to Kabat positions 241 (5241 P) and 248 (L248E).
  • the intracellular signaling domain may include any suitable T cell receptor (TCR) complex signaling domain, or portion thereof.
  • TCR T cell receptor
  • the intracellular signaling domain is derived from a CD3 complex.
  • the intracellular signaling domain is a TCR zeta-chain ( ⁇ -chain) signaling domain.
  • a ⁇ -chain signaling domain may include a nucleotide sequence which encodes an amino acid sequence as follows:
  • the intracellular signaling domain may be associated with any suitable costimulatory domain including, but not limited to, a 4-1BB costimulatory domain, an OX-40 costimulatory domain, a CD27 costimulatory domain, a CD28 costimulatory domain, a DAP10 costimulatory domain, an inducible costiumulatory (ICOS) domain, or a 2B4 costimulatory domain.
  • a CAR may include at least one costimulatory signaling domain.
  • the CAR has a single costimulatory signaling domain, or it may include two or more costimulatory signaling domains such as those described above.
  • the costimulatory domain may be made up of a single costimulatory domain such as those described above, or alternatively, may be made up of two or more portions of two or more costimulatory domains.
  • the CAR does not include a costimulatory signaling domain.
  • the CAR includes a costimulatory signaling domain which is a CD28 costimulatory domain.
  • such a modified CD28 costimulatory domain may have one or more amino acid substitutions or modifications including, but not limited to a substitution of leucine-leucine (LL) to glycine-glycine (GG).
  • a modified costimulatory signaling domain region may include a nucleotide sequence which encodes an amino acid sequence selected from the following:
  • the signaling domain or domains may include a transmembrane domain selected from a CD28 transmembrane domain, a CD3 transmembrane domain, or any other suitable transmembrane domain known in the art.
  • the transmembrane domain is a CD28 transmembrane domain.
  • a modified costimulatory signaling domain region may include a nucleotide sequence which encodes an amino acid sequence selected from the following:
  • the CAR gene is part of an expression cassette.
  • the expression cassette may—in addition to the CAR gene—also include an accessory gene.
  • the accessory gene When expressed by a T cell, the accessory gene may serve as a transduced T cell selection marker, an in vivo tracking marker, or a suicide gene for transduced T cells.
  • the accessory gene is a truncated EGFR gene (EGFRt).
  • EGFRt may be used as a non-immunogenic selection tool (e.g., immunomagnetic selection using biotinylated cetuximab in combination with anti-biotin microbeads for enrichment of T cells that have been lentivirally transduced with EGFRt-containing constructs), tracking marker (e.g., flow cytometric analysis for tracking T cell engraftment), and suicide gene (e.g., via Cetuximab/Erbitux® mediated antibody dependent cellular cytotoxicity (ADCC) pathways).
  • ADCC Cetuximab/Erbitux® mediated antibody dependent cellular cytotoxicity
  • EGFRt truncated EGFR
  • the accessory gene is a truncated CD19 gene (CD19t).
  • the accessory gene is an inducible suicide gene.
  • a suicide gene is a recombinant gene that will cause the cell that the gene is expressed in to undergo programmed cell death or antibody mediated clearance at a desired time.
  • an inducible suicide gene that may be used as an accessory gene is an inducible caspase 9 gene (see Straathof et al. (2005). An inducible caspase 9 safety switch for T-cell therapy. Blood . June 1; 105(11): 4247-4254, the subject matter of which is hereby incorporated by reference as if fully set forth herein).
  • the expression cassette that include a CAR gene described above may be inserted into a vector for delivery—via transduction or transfection—of a target cell.
  • Any suitable vector may be used, for example, a bacterial vector, a viral vector, or a plasmid.
  • the vector is a viral vector selected from a retroviral vector, a lentiviral vector, a poxvirus vector, an adenoviral vector, or an adeno-associated viral vector.
  • the vector may transduce a population of healthy immune cells, e.g., T cells. Successfully transduced or transfected target cells express the one or more genes that are part of the expression cassette.
  • one or more populations of immune cells may be transduced with a CAR gene such as those described above.
  • the transduced T cells may be from a donor, or may be from a subject having a cancer and who is in need of a treatment for the cancer.
  • the transduced T cells are used in an adoptive immunotherapy treatment for the treatment of the cancer (residues in bold/underline indicate substitutions).
  • the transduced T cells express a CAR gene that encodes an amino acid sequence selected from SEQ ID NOS:24-27:
  • CD19R(L235E)28Z (SEQ ID NO: 24): MLLLVTSLLL CELPHPAFLL IPDIQMTQTT SSLSASLGDR VTISCRASQD ISKYLNWYQQ KPDGTVKLLI YHTSRLHSGV PSRFSGSGSG TDYSLTISNL EQEDIATYFC QQGNTLPYTF GGGTKLEITG STSGSGKPGS GEGSTKGEVK LQESGPGLVA PSQSLSVTCT VSGVSLPDYG VSWIRQPPRK GLEWLGVIWG SETTYYNSAL KSRLTIIKDN SKSQVFLKMN SLQTDDTAIY YCAKHYYYGG SYAMDYWGQG TSVTVSSESK YGPPCPPCPA PEF E GGPSVF LFPPKPKDTL MISRTPEVTC VVVDVSQEDP EVQFNWYVDG VEVHNAKTKP REEQFNSTYR VVSVLTVLHQ D
  • the one or more populations of T cells may be part of a pharmaceutically acceptable composition for delivery for administration to a subject.
  • the pharmaceutically effective composition may include one or more pharmaceutically effective carriers.
  • a “pharmaceutically acceptable carrier” as used herein refers to a pharmaceutically acceptable material, composition, or vehicle that is involved in carrying or transporting a treatment of interest from one tissue, organ, or portion of the body to another tissue, organ, or portion of the body.
  • Such a carrier may comprise, for example, a liquid, solid, or semi-solid filler, solvent, surfactant, diluent, excipient, adjuvant, binder, buffer, dissolution aid, solvent, encapsulating material, sequestering agent, dispersing agent, preservative, lubricant, disintegrant, thickener, emulsifier, antimicrobial agent, antioxidant, stabilizing agent, coloring agent, or some combination thereof.
  • Each component of the carrier is “pharmaceutically acceptable” in that it must be compatible with the other ingredients of the composition and must be suitable for contact with any tissue, organ, or portion of the body that it may encounter, meaning that it must not carry a risk of toxicity, irritation, allergic response, immunogenicity, or any other complication that excessively outweighs its therapeutic benefits.
  • materials which can serve as pharmaceutically-acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) natural polymers such as gelatin, collagen, fibrin, fibrinogen, laminin, decorin, hyaluronan, alginate and chitosan; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as trimethylene
  • compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents and the like, for example, sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate and the like.
  • the pharmaceutically acceptable carrier is an aqueous carrier, e.g. buffered saline and the like.
  • the pharmaceutically acceptable carrier is a polar solvent, e.g. acetone and alcohol.
  • concentration of CAR-transduced T cells in these formulations can vary widely, and will be selected primarily based on fluid volumes, viscosities, organ size, body weight and the like in accordance with the particular mode of administration selected and the biological system's needs.
  • populations of T cells transduced with a CAR gene such as those described herein cells used in the methods for targeting and killing cancer or tumor cells may be grown in a cell culture.
  • the method may be used in an in vitro or research setting to investigate the role of a particular cancer-related antigen in the etiology of a cancer, or to evaluate the targeting abilities of new CAR constructs.
  • CAR genes and populations of T cells that are transduced with CAR genes such as those described above may be used in methods for treating cancer in a subject. Such methods may include a step of administering a therapeutically effective amount of at least one population of T cells transduced with at least one CAR gene to the subject.
  • the population of CAR-transduced T-cells expresses one or more CAR genes, such as those described above.
  • the T cells are transduced with and express a single mutant gene construct such as a CD19R(L235E) or CD19R(N297Q) construct as described herein, a double mutant gene construct which has both a L235E and N297Q mutation (e.g., CD19R(EQ)), as described herein, or a deletion gene construct (e.g., CD19Rch2 ⁇ ), as described herein.
  • a single mutant gene construct such as a CD19R(L235E) or CD19R(N297Q) construct as described herein
  • a double mutant gene construct which has both a L235E and N297Q mutation e.g., CD19R(EQ)
  • a deletion gene construct e.g., CD19Rch2 ⁇
  • Cancers that may be treated using the population of transduced T cells may include, but are not limited to, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Adrenocortical, Carcinoma, AIDS-Related Cancers, Anal Cancer, Appendix Cancer, Astrocytomas, Atypical Teratoid/Rhabdoid Tumor, Central Nervous System, Basal Cell Carcinoma, Bile Duct Cancer, Bladder Cancer, Bone Cancer, Osteosarcoma and Malignant Fibrous Histiocytoma, Brain Stem Glioma, Brain Tumors, Breast Cancer, Bronchial Tumors, Burkitt Lymphoma, Carcinoid Tumors, Central Nervous System Cancers, Cervical Cancer, Chordoma, Chronic Lymphocytic Leukemia (CLL), Chronic Myelogenous Leukemia (CML), Chronic Myeloproliferative Disorders, Colon Cancer, Colorectal Cancer, Cran
  • the population or populations of T cells transduced with the CAR gene or genes that may be used in accordance with the methods described herein may be administered, by any suitable route of administration, alone or as part of a pharmaceutical composition.
  • a route of administration may refer to any administration pathway known in the art, including but not limited to intracranial, parenteral, or transdermal.
  • Parenter refers to a route of administration that is generally associated with injection, including infraorbital, infusion, intraarterial, intracapsular, intracardiac, intradermal, intramuscular, intraperitoneal, intrapulmonary, intraspinal, intrasternal, intrathecal, intratumoral, intrauterine, intravenous, subarachnoid, subcapsular, subcutaneous, transmucosal, or transtracheal.
  • transduced T cells are administered intravenously or intrathecally.
  • an effective amount refers to an amount of an agent, compound, treatment or therapy that produces a desired effect.
  • a population of cells may be contacted with an effective amount of an agent, compound, treatment or therapy to study its effect in vitro (e.g., cell culture) or to produce a desired therapeutic effect ex vivo or in vitro.
  • An effective amount of an agent, compound, treatment or therapy may be used to produce a therapeutic effect in a subject, such as preventing or treating a target condition, alleviating symptoms associated with the condition, or producing a desired physiological effect.
  • the effective amount of a compound is a “therapeutically effective amount,” “therapeutically effective concentration” or “therapeutically effective dose.”
  • the precise effective amount or therapeutically effective amount is an amount of the composition that will yield the most effective results in terms of efficacy of treatment in a given subject or population of cells. This amount will vary depending upon a variety of factors, including but not limited to the characteristics of the compound (including activity, pharmacokinetics, pharmacodynamics, and bioavailability), the physiological condition of the subject (including age, sex, disease type and stage, general physical condition, responsiveness to a given dosage, and type of medication) or cells, the nature of the pharmaceutically acceptable carrier or carriers in the formulation, and the route of administration.
  • an effective or therapeutically effective amount may vary depending on whether the compound is administered alone or in combination with another compound, drug, therapy or other therapeutic method or modality.
  • One skilled in the clinical and pharmacological arts will be able to determine an effective amount or therapeutically effective amount through routine experimentation, namely by monitoring a cell's or subject's response to administration of a compound and adjusting the dosage accordingly.
  • Remington The Science and Practice of Pharmacy, 21 st Edition, Univ. of Sciences in Philadelphia (USIP), Lippincott Williams & Wilkins, Philadelphia, Pa., 2005, which is hereby incorporated by reference as if fully set forth herein.
  • Agents, compounds treatments or therapies that may be used in an effective amount or therapeutically effective amount to produce a desired effect in accordance with the embodiments described herein may include, but are not limited to, a CAR gene, an expression cassette that includes a CAR gene, a vector that delivers an expression cassette that includes a CAR gene to a target cell such as a T cell, and a population of T cells that are transduced with a CAR gene.
  • treating may refer to preventing the condition, slowing the onset or rate of development of the condition, reducing the risk of developing the condition, preventing or delaying the development of symptoms associated with the condition, reducing or ending symptoms associated with the condition, generating a complete or partial regression of the condition, or some combination thereof.
  • Treatment may also mean a prophylactic or preventative treatment of a condition.
  • subject refers to a human or animal, including all mammals such as primates (particularly higher primates), sheep, dog, rodents (e.g., mouse or rat), guinea pig, goat, pig, cat, rabbit, and cow. In some embodiments, the subject is a human.
  • the methods for treating cancer may include a step of administering a therapeutically effective amount of a first population of T cells transduced with a first CAR gene in combination with a therapeutically effective amount of a second population of T cells transduced with a second CAR gene.
  • CAR-transduced T cells may be administered in combination with one or more additional anti-cancer therapies.
  • “In combination” or “in combination with,” as used herein, means in the course of treating the same cancer in the same subject using two or more agents, drugs, therapeutics, procedures, treatment regimens, treatment modalities or a combination thereof, in any order. This includes simultaneous administration, as well as in a temporally spaced order of up to several days apart.
  • Such combination treatment may also include more than a single administration of any one or more of the agents, drugs, therapeutics, procedures, treatment regimens, and treatment modalities.
  • the administration of the two or more agents, drugs, therapeutics, procedures, treatment regimens, treatment modalities or a combination thereof may be by the same or different routes of administration.
  • Additional anti-cancer therapies may include one or more anti-cancer procedures, treatment modalities, anti-cancer therapeutics or a combination thereof.
  • the CAR-transduced T cells may be administered in combination with one or more anti-cancer procedures or treatment modalities including, but not limited to, stem cell transplantation (e.g., bone marrow transplant or peripheral blood stem cell transplant using allogenic stem cells, autologous stem cells; or a non-myeloablative transplant), radiation therapy, or surgical resection.
  • stem cell transplantation e.g., bone marrow transplant or peripheral blood stem cell transplant using allogenic stem cells, autologous stem cells; or a non-myeloablative transplant
  • radiation therapy e.g., radiation therapy, or surgical resection.
  • the CAR-transduced T cells may be administered in combination with one or more anti-cancer therapeutics or drugs that may be used to treat cancer including, but not limited to, chemotherapeutics and other anti-cancer drugs, immunotherapeutics, targeted therapeutics, or a combination thereof.
  • Chemotherapeutics and other anti-cancer drugs that may be administered in combination with the CAR-transduced T cells in accordance with the embodiments described herein include, but are not limited to, all-trans-retinoic acid (ATRA), arsenic trioxide, anthracycline antibiotics and pharmaceutically acceptable salts thereof (e.g., doxorubicin hydrochloride, daunorubicin hydrochloride, idarubicin, mitoxantrone), alkylating agents (e.g., cyclophosphamide, laromustine), antimetabolite analogs (cytarabine, 6-thioguanine, 6-mercaptopurine, methotrexate), demethylating agents (e.g., decitabine, 5-azacytidine), nucleic acid synthesis inhibitors (e.g., hydroxyurea), topoisomerase inhibitors (e.g., etoposide), vinca alkaloids (e.g., vincri
  • Immunotherapeutics that may be administered in combination with the CAR-transduced T cells in accordance with the embodiments described herein include, but are not limited to, immune modulatory reagents (e.g., STAT3 inhibitors, Lenalidomide) and therapeutic monoclonal antibodies.
  • immune modulatory reagents e.g., STAT3 inhibitors, Lenalidomide
  • therapeutic monoclonal antibodies may be designed to target one or more additional cancer-related antigens
  • Targeted therapeutics that may be administered in combination with the CAR-transduced T cells in accordance with the embodiments described herein include, but are not limited to, tyrosine kinase inhibitors (imatinib, dasatinib, nilotinib, sunitinib), farnesyl transferase inhibitors (e.g., tipifarnib), FLT inhibitors, and c-Kit (or CD117) inhibitors (imatinib, dasatinib, nilotinib).
  • tyrosine kinase inhibitors imatinib, dasatinib, nilotinib, sunitinib
  • farnesyl transferase inhibitors e.g., tipifarnib
  • FLT inhibitors e.g., tipifarnib
  • c-Kit (or CD117) inhibitors imatinib, dasatinib, nilotinib.
  • CARs Chimeric Antigen Receptors Incorporating Mutations in the IgG4 Fc Spacer Region Avoid Fc Receptor Mediated Recognition and Clearance of CAR T Cells, Resulting in Improved T Cell Persistence and Anti-Tumor Efficacy
  • CD19-specific CAR that has been mutated at one or two sites within the CH2 region (L235E and/or N297Q) of its IgG4 Fc spacer—referred to herein as CD19R(L235E), CD19R(N297Q) or CD19R(EQ)—as well as a CD19-specific CAR that has a CH2 deletion in its IgG4 Fc spacer—referred to herein as CD19Rch2 ⁇ .
  • T cells expressing these mutated CAR were then compared to T cells expressing a non-mutated CAR (CD19R) or only a truncated EGFR molecule (EGFRt) as a tracking marker (Wang et al. 2011), for in vitro Fc ⁇ R binding and CAR-mediated cytolytic activity, as well as in vivo engraftment and therapeutic efficacy.
  • CD19R non-mutated CAR
  • EGFRt truncated EGFR molecule
  • the CD19R28Z-T2A-EGFRt_epHIV7 lentiviral construct contains a) the chimeric antigen receptor (CAR) sequence consisting of the V H and V L gene segments of the CD19-specific FMC63 mAb, an IgG4 hinge-C H2 —C H3 , the transmembrane and cytoplasmic signaling domains of the costimulatory molecule CD28 that contains gg mutations that enhance chimeric receptor expression and function (Nguyen et al. 2003), and the cytoplasmic domain of the CD3 ⁇ chain (Kowolik et al.
  • CAR chimeric antigen receptor
  • CD19R(L235E)28Z-T2A-EGFRt_epHIV7, CD19R(N297Q)28Z-T2A-EGFRt_epHIV7 and CD19R(EQ)28Z-T2A-EGFRt_epHIV7 vectors were generated by site directed mutagenesis using the QuikChange II XL kit (Agilent Technologies, Santa Clara, Calif.) of a codon optimized CD19R28Z_pGA plasmid that had been synthesized by Geneart, digested with NheI/RsrII and ligated with a similarly digested CD19R28Z-T2A-EGFRt_epHIV7.
  • the CD19Rch2 ⁇ 28Z-T2A-EGFRt_epHIV7 vector was generated from a codon optimized CD19R-HL-CH3(CO)_pMK-RQ plasmid that had been synthesized by Geneart, digested with NheI/RsrII and ligated with a similarly digested CD19R28Z-T2A-EGFRt_epHIV7.
  • PBMCs Human peripheral blood mononuclear cells
  • COHNMC City of Hope National Medical Center
  • EBV-transformed lymphoblastoid cell lines (LCL) and LCL that expressed OKT3 (LCL-OKT3) (Wang et al. 2011 b) or ffLuc + LCL cells were cultured in RPMI 1640 (Irvine Scientific, Santa Ana, Calif.) supplemented with 10% heat-inactivated fetal calf serum (FCS, Hyclone, Logan, Utah) 2 mM L-glutamine (Irvine Scientific), and 25 mM HEPES (Irvine Scientific).
  • ffLuc+ LCL were generated by transduction with lentiviral vector eGFP-ffluc_epHIV7 at an MOI of 20 in the presence of 5 ⁇ g/mL polybrene in 500 uL medium, and subsequent purification by sorting GFP+ cells.
  • Mouse myeloma cells secreting human homeostatic IL-15 cytokine (NSO-IL15) were generated as previously described (Wang et al. 2011b).
  • SupB15 and K562 leukemia cell lines were grown in the corresponding ATCC recommended media.
  • Fluorochrome-conjugated isotype controls anti-CD3, anti-CD4, anti-CD8, anti-CD45 and streptavidin were obtained from BD Biosciences (San Jose, Calif.). Biotinylated anti-Fc was purchased from Jackson ImmunoResearch Laboratories, Inc. (West Grove, Pa.). Generation of biotinylated-cetuximab was previously described (Wang et al. 2011a). Biotinylated huFc ⁇ R1, muFc ⁇ R1, huFc ⁇ R2a, huFc ⁇ R2b, and muFc ⁇ R2b were obtained from Sino Biological, Inc. (Beijing, P.R. China). The percentage of immunofluorescent cells were analyzed by a FACScalibur system (BD Biosciences), and the percentage of cells in a region of analysis were calculated using FCS Express V3 (De Novo Software, CA, USA).
  • mice 6-10 week old NOD/Scid IL-2R ⁇ C null (NSG) mice were injected intravenously (i.v.) on day 0 with 10 7 of the indicated T CM -derived cells, and intraperitoneal (i.p.) injections three times a week of 2 ⁇ 10 7 irradiated NS0-IL15 to provide a systemic supply of human IL-15 in vivo.
  • Peripheral blood was harvested from retro-orbital bleeds, red blood cells were lysed and cell suspensions were analyzed by flow cytometry.
  • 1.5 ⁇ 10 6 ffLuc + LCL cells were administered i.v.
  • T CM Central memory T cells
  • the CD19R construct includes a CD19-specific scFv derived from mouse monoclonal antibody FMC63, a human IgG4 Fc linker, human CD28 transmembrane and cytoplasmic domains, and a human CD3-zeta cytoplasmic domain. Because the CAR construct includes a portion of a human IgG4 Fc region, the propensity of FcR-mediated innate immune responses to selectively clear the CD19R/EGFRt+ cells—but not the EGFRt+ cells—was investigated.
  • a binding assay using soluble human Fc ⁇ R1 revealed that, in contrast to T CM -derived cells that were non-transduced or expressed only the EGFRt, those that expressed CD19R exhibited binding of the Fc ⁇ R1 molecules that could be titrated down with higher dilutions ( FIG. 2 ).
  • NSG mice while immunodeficient, are known to still have FcR-expressing neutrophils and monocytes (Ishikawa et al. 2005; Ito et al. 2002), thus providing a potential rationale for the lack of CAR+ T cell persistence observed in prior engraftment studies.
  • the CD19-specific CAR was mutated at amino acids within the IgG4 CH2 domain that may be involved with FcR binding—L235E and/or N297Q ( FIG. 3 a ).
  • a CD19-specific CAR with a deletion of the IgG4 CH2 domain i.e., a deletion of the domain that contains residues 235 and 297) was also generated ( FIG. 3 a ).
  • flow cytometric analysis was performed using various human and murine biotinylated soluble Fc ⁇ Rs, and PE-streptavidin (SA-PE) to detect the binding of the Fc ⁇ Rs to the different cell populations.
  • T cells that expressed the non-mutated CD19R were bound by human Fc ⁇ R1, Fc ⁇ R2a and Fc ⁇ R2b, as well as murine Fc ⁇ R1 and Fc ⁇ R2b ( FIG. 4 ).
  • T cells that expressed only EGFRt were not bound by these Fc ⁇ Rs, and T cells that expressed either the CD19R(N297Q), CD19R(L235E) or CD19R(EQ) mutants, or the CD19Rch2 ⁇ deletion all displayed significantly reduced binding to these Fc ⁇ Rs.
  • LCL is a CD19-expressing tumor cell line that was transduced to express firefly luciferase (ffLuc) to allow for bioluminescent monitoring of in vivo tumor growth.
  • ffLuc+ LCL Three days after the ffLuc+ LCL were administered to NSG mice i.v., the mice were treated i.v. with either PBS as a control or 5 ⁇ 10 6 T cells expressing either the non-mutated CD19R, the EGFRt marker alone, the double point-mutated CD19R(EQ), or the CH2-deleted CD19Rch2 ⁇ .
  • CAR chimeric antigen receptor
  • an Ig Fc spacer can potentially inhibit the engraftment and/or persistence of CAR-expressing cells in NSG mouse models in a manner that correlates with Fc ⁇ R binding.
  • Prevention of Fc ⁇ R binding by either point mutation or deletion of the relevant sequences within the CAR Fc domain can then restore the in vivo persistence of the adoptively transferred cells to that of cells which do not express a CAR.
  • the increased in vivo persistence that is mediated by the spacer-optimized CAR then translates, into significantly improved CAR-directed anti-tumor therapy in an in vivo mouse model.
  • the immunological clearance of adoptively transferred T cells is not a new issue.
  • cellular immune rejection responses against the HyTK and NeoR selection genes have been shown to be coordinately expressed with the CAR (Berger et al. 2006; Jensen et al. 2010).
  • the studies described above highlights the importance of FcR-mediated responses against CAR-expressing T cells for in vivo T cell persistence and anti-tumor efficacy. Consequently, the studies also show that there is a ‘fix’ to avoid this form of immunogenicity—namely, the incorporation of mutations in the CAR design to prevent Fc ⁇ R-recognition.
  • the mutations described herein may be extrapolated to humans and should therefore augment the persistence and therapeutic efficacy of T cells expressing IgG-spacer containing CAR in humans. Any discrepancy in CAR T cell engraftment and in vivo anti-tumor efficacy is likely impacted by the nature of the murine NSG model system.
  • Human IgG4 has been shown to efficiently bind murine FcRs to mediate potent antibody dependent cell-mediated cytotoxicity (Isaacs et al. Steplewski et al. 1988).
  • human FcRs have the strongest affinity toward IgG1 and IgG3, and reduced affinity for IgG4 (Schroeder & Cavacini 2010; Nirula et al. 2011). Additionally, given that NSG mice lack serum antibodies, FcRs expressed by their innate immune cells are unoccupied and thus have a greater potential to bind the IgG-Fc spacer within the CAR. With the exception of hypoglobulinemia cases, immunocompetent humans have high serum IgG levels of approximately 10 mg/mL (Stoop et al., 1969), which could potentially compete for recognition of IgG-containing CARs.
  • CARs containing components of an Ig Fc spacer should incorporate modifications that prevent the FcR-mediated recognition of the cells in vivo.
  • modifications can involve either point mutations to change the amino acid sequence, or sequence deletions such as that seen with the CD19R(EQ) and CD19Rch2 ⁇ constructs described herein.
  • modifications prevent the ability of FcR-expressing cells to recognize the CAR-expressing immunotherapeutic cellular product in vivo, but they might also prevent the unintentional activation of the transferred T cells and/or the host immune responses (Hombach et al. 2010), which could contribute to various unwanted side-effects of this immunotherapeutic strategy.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US15/111,384 2014-01-13 2014-03-14 CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USE Abandoned US20160333108A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/111,384 US20160333108A1 (en) 2014-01-13 2014-03-14 CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USE

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461926881P 2014-01-13 2014-01-13
PCT/US2014/028961 WO2015105522A1 (en) 2014-01-13 2014-03-14 Chimeric antigen receptors (cars) having mutations in the fc spacer region and methods for their use
US15/111,384 US20160333108A1 (en) 2014-01-13 2014-03-14 CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USE

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/028961 A-371-Of-International WO2015105522A1 (en) 2014-01-13 2014-03-14 Chimeric antigen receptors (cars) having mutations in the fc spacer region and methods for their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/221,257 Continuation US20200040096A1 (en) 2014-01-13 2018-12-14 CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USE

Publications (1)

Publication Number Publication Date
US20160333108A1 true US20160333108A1 (en) 2016-11-17

Family

ID=53524229

Family Applications (3)

Application Number Title Priority Date Filing Date
US15/111,384 Abandoned US20160333108A1 (en) 2014-01-13 2014-03-14 CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USE
US16/221,257 Abandoned US20200040096A1 (en) 2014-01-13 2018-12-14 CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USE
US17/510,099 Pending US20220372164A1 (en) 2014-01-13 2021-10-25 CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USE

Family Applications After (2)

Application Number Title Priority Date Filing Date
US16/221,257 Abandoned US20200040096A1 (en) 2014-01-13 2018-12-14 CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USE
US17/510,099 Pending US20220372164A1 (en) 2014-01-13 2021-10-25 CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USE

Country Status (8)

Country Link
US (3) US20160333108A1 (de)
EP (2) EP3626748A1 (de)
JP (1) JP6560235B2 (de)
CN (2) CN107074957B (de)
AU (3) AU2014376328A1 (de)
CA (1) CA2936501A1 (de)
ES (1) ES2767423T3 (de)
WO (1) WO2015105522A1 (de)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170360910A1 (en) * 2014-12-05 2017-12-21 City Of Hope Cs1 targeted chimeric antigen receptor-modified t cells
WO2020056045A1 (en) * 2018-09-13 2020-03-19 Nkarta, Inc. Natural killer cell compositions and immunotherapy methods for treating tumors
US10982258B2 (en) * 2015-04-27 2021-04-20 Abvitro Llc Methods of sequencing, determining, pairing, and validating therapeutic agents and disease specific antigens
US11059879B2 (en) 2015-10-27 2021-07-13 Board Of Regents, The University Of Texas System Chimeric antigen receptor molecules and uses thereof
US11066457B2 (en) * 2017-02-08 2021-07-20 Cellular Biomedicine Group Hk Limited Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof
US20210277148A1 (en) * 2018-07-18 2021-09-09 Amgen Inc. Chimeric receptors to steap1 and methods of use thereof
US11154575B2 (en) 2019-03-05 2021-10-26 Nkarta, Inc. Cancer immunotherapy using CD19-directed chimeric antigen receptors
US20220049004A1 (en) * 2019-05-07 2022-02-17 Gracell Biotechnologies (Shanghai) Co., Ltd. Engineered immune cells targeting bcma and their uses thereof
WO2022129692A1 (en) * 2020-12-16 2022-06-23 Orion Corporation Chimeric antigen receptor (car) spacer modifications enhance car t cell functionality
US11608517B2 (en) 2016-07-12 2023-03-21 Kite Pharma, Inc. Antigen binding molecules and methods of use thereof
US11883432B2 (en) 2020-12-18 2024-01-30 Century Therapeutics, Inc. Chimeric antigen receptor system with adaptable receptor specificity

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2948544A4 (de) 2013-01-28 2016-08-03 St Jude Childrens Res Hospital Chimärer rezeptor mit nkg2d-spezifität für zelltherapie gegen krebs und infektionskrankheiten
TW201446794A (zh) 2013-02-20 2014-12-16 Novartis Ag 利用抗－ｃｄ１２３嵌合抗原受體工程化ｔ細胞之初級人類白血病有效靶向
US9657105B2 (en) 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
RS61223B1 (sr) 2013-12-20 2021-01-29 Hutchinson Fred Cancer Res Označeni himerni efektorski molekuli i njihovi receptori
KR102509481B1 (ko) 2014-04-10 2023-03-10 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 규정된 조성물 유전자 변형된 t-세포 생성물
EP3143134B1 (de) 2014-05-15 2020-10-28 National University of Singapore Modifizierte natürliche killerzellen und verwendungen davon
CN107108744B (zh) 2014-08-19 2020-09-25 诺华股份有限公司 抗cd123嵌合抗原受体(car)用于癌症治疗
GB201504840D0 (en) 2015-03-23 2015-05-06 Ucl Business Plc Chimeric antigen receptor
WO2016176652A2 (en) 2015-04-29 2016-11-03 Fred Hutchinson Cancer Research Center Modified stem cells and uses thereof
EP3842448A1 (de) 2015-05-15 2021-06-30 City of Hope Chimäre antigenrezeptorzusammensetzungen
CN108174604B (zh) * 2015-08-07 2023-06-23 西雅图儿童医院（Dba西雅图儿童研究所） 用于实体瘤靶向的双特异性car t细胞
KR20180037294A (ko) 2015-08-31 2018-04-11 블루버드 바이오, 인코포레이티드. 항-시알릴 Tn 키메라 항원 수용체
BR112018006991A2 (pt) * 2015-10-06 2018-10-16 Hope City receptores de antígeno quiméricos direcionados ao psca
EP3362470B1 (de) * 2015-10-13 2021-09-22 City of Hope Chimäre antigenrezeptoren mit einer chlorotoxindomäne
CN108779174B (zh) * 2015-11-04 2022-11-29 希望之城公司 靶向her2的嵌合抗原受体
IL287889B2 (en) * 2016-02-05 2024-03-01 Hope City Administration of transgenic T cells for the treatment of central nervous system cancer
CN109415409B (zh) * 2016-04-01 2022-03-15 亘喜生物科技（上海）有限公司 Flag标记的cd19-car-t细胞
SG11201810640RA (en) * 2016-06-08 2018-12-28 Intrexon Corp Cd33 specific chimeric antigen receptors
CN106117366A (zh) * 2016-06-24 2016-11-16 安徽未名细胞治疗有限公司 一种cd19特异性嵌合抗原受体及其编码基因、应用
CA3039136A1 (en) 2016-09-02 2018-03-08 The Regents Of The University Of California Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
US20190263928A1 (en) * 2016-09-30 2019-08-29 Baylor College Of Medicine Adaptive chimeric antigen receptor t-cell design
WO2018075813A1 (en) 2016-10-19 2018-04-26 City Of Hope Use of endogenous viral vaccine in chimeric antigen receptor t cell therapy
CN110291200B (zh) 2016-12-12 2024-05-14 西雅图儿童医院（Dba西雅图儿童研究所） 对哺乳动物细胞中转基因表达的药剂配体诱导具有增大的灵敏度的嵌合转录因子变异体
US11896616B2 (en) 2017-03-27 2024-02-13 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
SG11201908492PA (en) 2017-03-27 2019-10-30 Nat Univ Singapore Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
EP3618842B1 (de) * 2017-05-01 2023-10-18 Juno Therapeutics, Inc. Kombination einer zelltherapie und einer immunmodulatorischen verbindung
WO2019051128A1 (en) * 2017-09-06 2019-03-14 Fred Hutchinson Cancer Research Center SPECIFIC STREP LABEL CHIMERIC RECEPTORS AND USES THEREOF
WO2019060713A1 (en) * 2017-09-22 2019-03-28 Kite Pharma, Inc. ANTIGEN-BINDING MOLECULES AND METHODS OF USE THEREOF
WO2019089982A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
EP3707246B1 (de) * 2017-11-07 2023-06-07 City of Hope Behandlung von zns-lymphom und systemischem lymphom mit intracerebroventrikulär verabreichtem cd19-car
CN109971723B (zh) * 2017-12-28 2023-07-07 上海细胞治疗研究院 包含CD40抗体与muc1特异性嵌合抗原受体基因的T细胞及其用途
CN109971717B (zh) * 2017-12-28 2023-06-20 上海细胞治疗研究院 共表达cd40抗体与间皮素特异性嵌合抗原受体的t细胞及其用途
CN109971722B (zh) * 2017-12-28 2023-09-01 上海细胞治疗研究院 靶向cd19且高水平稳定表达cd40抗体的car-t细胞及其用途
CN109971716B (zh) * 2017-12-28 2023-08-01 上海细胞治疗研究院 自分泌cd47抗体的egfr特异性car-t细胞及其用途
CN109971721B (zh) * 2017-12-28 2023-10-31 上海细胞治疗研究院 自表达cd47抗体的间皮素特异性car-t细胞及其用途
CN109971725B (zh) * 2017-12-28 2024-02-02 上海细胞治疗研究院 抗体修饰的嵌合抗原受体修饰t细胞及其用途
CN109971714B (zh) * 2017-12-28 2023-06-20 上海细胞治疗研究院 自表达pd-1抗体并靶向间皮素的嵌合抗原受体修饰t细胞及其用途
CN109971712B (zh) * 2017-12-28 2023-06-20 上海细胞治疗研究院 特异性靶向cd19抗原且高水平稳定表达pd-1抗体的car-t细胞及用途
BR112020014913A2 (pt) * 2018-01-22 2020-12-08 Seattle Children's Hospital (dba Seattle Children's Research Institute) Métodos para uso de células t car
CA3091138A1 (en) * 2018-02-26 2019-08-29 Fred Hutchinson Cancer Research Center Compositions and methods for cellular immunotherapy
CA3103610A1 (en) * 2018-06-12 2019-12-19 The Regents Of The University Of California Single-chain bispecific chimeric antigen receptors for the treatment of cancer
CN109096405B (zh) * 2018-09-20 2021-07-09 杭州普略生物科技有限公司 以gd2为靶点的嵌合抗原受体及药物组合物
EP3861854A4 (de) * 2018-09-27 2022-01-26 Central Institute For Experimental Animals Immundefiziente maus
CN113784733A (zh) * 2019-05-07 2021-12-10 亘喜生物科技（上海）有限公司 靶向bcma的工程化免疫细胞及其用途
CN111499763A (zh) * 2020-03-31 2020-08-07 江苏省省级机关医院 一种靶向mage-a1的特异性全人源嵌合抗原受体及其应用
US20230159644A1 (en) * 2020-04-17 2023-05-25 City Of Hope Flt3-targeted chimeric antigen receptor modified cells for treatment of flt3-positive malignancies
WO2021225532A1 (en) * 2020-05-08 2021-11-11 Mahidol University A chimeric antigen receptor and modified cells carrying the receptor
TW202228735A (zh) 2020-09-10 2022-08-01 美商野馬生物股份有限公司 包含癌症靶向之car-t細胞的組合療法以及將其用於癌症治療的方法
CN112111014A (zh) * 2020-09-22 2020-12-22 廖文强 一种抗氧化嵌合型抗原受体和免疫细胞
CN116848147A (zh) * 2020-11-20 2023-10-03 先声再明医药有限公司 Cd19人源化抗体及其应用
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
CN117004604A (zh) * 2022-04-28 2023-11-07 南京北恒生物科技有限公司 一种ciita基因被敲除的工程化免疫细胞及其用途
WO2024026107A2 (en) * 2022-07-28 2024-02-01 Lentigen Technology, Inc. Chimeric antigen receptor therapies for treating solid tumors
CN116254230A (zh) * 2022-09-14 2023-06-13 卡瑞济(北京)生命科技有限公司 用于制备和扩增通用型人源化抗cd19 car-nk细胞的方法及其用途
CN117942275A (zh) * 2022-10-31 2024-04-30 康码（上海）生物科技有限公司 一种基于病毒阻断剂的洗手液及其应用
WO2024118866A1 (en) 2022-12-01 2024-06-06 Modernatx, Inc. Gpc3-specific antibodies, binding domains, and related proteins and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8414892B2 (en) * 2000-10-18 2013-04-09 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
US20020102264A1 (en) * 2000-10-18 2002-08-01 Cheung Nai-Kong V. Uses of monoclonal antibody 8H9
PT2250279E (pt) * 2008-02-08 2016-06-03 Medimmune Llc Anticorpos anti-ifnár1 com afinidade reduzida para o ligando fc
CA2779526C (en) * 2009-11-03 2022-12-06 City Of Hope Truncated epiderimal growth factor receptor (egfrt) for transduced t cell selection
ES2754394T3 (es) * 2010-09-08 2020-04-17 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Receptores de antígenos quiméricos con una región bisagra optimizada
DK2649086T3 (en) * 2010-12-09 2017-09-18 Univ Pennsylvania USING CHEMICAL ANTIGEN RECEPTOR-MODIFIED T-CELLS TO TREAT CANCER
EP3424953B1 (de) * 2011-06-06 2020-08-05 Novo Nordisk A/S Therapeutische antikörper
EP2814846B1 (de) * 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispezifische chimäre antigenrezeptoren und therapeutische verwendungen davon
US9657105B2 (en) * 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170360910A1 (en) * 2014-12-05 2017-12-21 City Of Hope Cs1 targeted chimeric antigen receptor-modified t cells
US11730797B2 (en) 2014-12-05 2023-08-22 City Of Hope CS1 targeted chimeric antigen receptor-modified T cells
US10821161B2 (en) * 2014-12-05 2020-11-03 City Of Hope CS1 targeted chimeric antigen receptor-modified T cells
US10982258B2 (en) * 2015-04-27 2021-04-20 Abvitro Llc Methods of sequencing, determining, pairing, and validating therapeutic agents and disease specific antigens
US11059879B2 (en) 2015-10-27 2021-07-13 Board Of Regents, The University Of Texas System Chimeric antigen receptor molecules and uses thereof
US11608517B2 (en) 2016-07-12 2023-03-21 Kite Pharma, Inc. Antigen binding molecules and methods of use thereof
US11608369B2 (en) 2017-02-08 2023-03-21 Cellular Biomedicine Group, Inc. Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof
US11472858B2 (en) 2017-02-08 2022-10-18 Cellular Biomedicine Group Hk Limited Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof
US11066457B2 (en) * 2017-02-08 2021-07-20 Cellular Biomedicine Group Hk Limited Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof
US11618778B2 (en) 2017-02-08 2023-04-04 Cellular Biomedicine Group Inc. Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof
US20210277148A1 (en) * 2018-07-18 2021-09-09 Amgen Inc. Chimeric receptors to steap1 and methods of use thereof
WO2020056045A1 (en) * 2018-09-13 2020-03-19 Nkarta, Inc. Natural killer cell compositions and immunotherapy methods for treating tumors
US11154575B2 (en) 2019-03-05 2021-10-26 Nkarta, Inc. Cancer immunotherapy using CD19-directed chimeric antigen receptors
US11253547B2 (en) 2019-03-05 2022-02-22 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
US20220049004A1 (en) * 2019-05-07 2022-02-17 Gracell Biotechnologies (Shanghai) Co., Ltd. Engineered immune cells targeting bcma and their uses thereof
US11840575B2 (en) * 2019-05-07 2023-12-12 Gracell Biotechnologies (Shanghai) Co., Ltd. Engineered immune cells targeting BCMA and their uses thereof
WO2022129692A1 (en) * 2020-12-16 2022-06-23 Orion Corporation Chimeric antigen receptor (car) spacer modifications enhance car t cell functionality
US11883432B2 (en) 2020-12-18 2024-01-30 Century Therapeutics, Inc. Chimeric antigen receptor system with adaptable receptor specificity

Also Published As

Publication number Publication date
AU2023203097A1 (en) 2023-06-08
WO2015105522A1 (en) 2015-07-16
AU2014376328A1 (en) 2016-07-21
CN107074957A (zh) 2017-08-18
JP2017507919A (ja) 2017-03-23
EP3626748A1 (de) 2020-03-25
EP3094653A1 (de) 2016-11-23
EP3094653B1 (de) 2019-10-23
CA2936501A1 (en) 2015-07-16
US20200040096A1 (en) 2020-02-06
CN113307880A (zh) 2021-08-27
CN107074957B (zh) 2021-05-07
EP3094653A4 (de) 2017-08-30
AU2020204351A1 (en) 2020-07-16
JP6560235B2 (ja) 2019-08-14
ES2767423T3 (es) 2020-06-17
US20220372164A1 (en) 2022-11-24

Similar Documents

Publication Publication Date Title
US20220372164A1 (en) CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USE
US11918606B2 (en) CD123-specific chimeric antigen receptor redirected t cells and methods of their use
CA3222300A1 (en) Bispecific binding agents binding to cldn18.2 and cd3

Legal Events

Date Code Title Description
AS Assignment

Owner name: CITY OF HOPE, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MARDIROS, ARMEN;REEL/FRAME:040216/0641

Effective date: 20161102

AS Assignment

Owner name: CITY OF HOPE, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MARDIROS, ARMEN;REEL/FRAME:040244/0689

Effective date: 20161102

AS Assignment

Owner name: CITY OF HOPE, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FORMAN, STEPHEN J.;BROWN, CHRISTINE E.;JONNALAGADDA, UMA MAHESWARA RAO;REEL/FRAME:041069/0239

Effective date: 20170124

AS Assignment

Owner name: CITY OF HOPE, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FORMAN, STEPHEN J.;BROWN, CHRISTINE E.;JONNALAGADDA, UMA MAHESWARA RAO;REEL/FRAME:041988/0042

Effective date: 20170124

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION